Difference between revisions of "Periampullary adenocarcinoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "*Surgery" to "*Surgery")
Line 54: Line 54:
 
''No adjuvant therapy.''
 
''No adjuvant therapy.''
 
====Preceding treatment====
 
====Preceding treatment====
*[[Surgery]]
+
*[[Surgery#Hepatobiliary_cancer|Surgery]]
  
 
===References===
 
===References===

Revision as of 03:23, 22 November 2018


Section editor Page editor
Nkv.jpg
Neeta K. Venepalli, MD, MBA
Chicago, IL
Ivy Abraham.JPG
Ivy Abraham, MD
Chicago, IL
0 regimens on this page
0 variants on this page


Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.

Guidelines

ESMO

NCCN

Adjuvant therapy

Observation

back to top

Regimen

Study Evidence Comparator Efficacy
Takada et al. 2002 Phase III (C) 5-FU & Mitomycin Seems not superior
Neoptolemos et al. 2012 (ESPAC-3) Phase III (C) 1. 5-FU & Leucovorin
2. Gemcitabine
Seems not superior

No adjuvant therapy.

Preceding treatment

References

  1. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. link to original article PubMed
  2. ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed